The Day In Review: Preos From NS Pharma, Inc. Gets Approvable Letter

March 10, 2006 – NPS Pharma received an approvable letter for Preos, its injectible osteoporosis therapy, but the agency wants more information about hypercalcemia; Noven said the FDA gave April 9, 2006 as the date for a decision on Daytrana, its ADHD patch; the FDA advised that Gemzar from Lilly does not improve survival in ovarian cancer; CV Therapeutics began shipping Ranexa, its novel anti-angina medication; Gen-Probe issued a non-exclusive license for its assay technology to Alnylam; BioSante Pharma presented data showing that Bio-E-Gel, a transdermal estradiol gel, ended hot flashes in 25% to 52% of women; Berlex partnered with ChemDiv to discover compounds that will target specified GPCR sites; and PerkinElmer bought a proteomics labeling technology from Agilix. The Centient Biotech 200™ was 5 points higher at 3975.41, a gain of .12%. More details...